SCHEMBL2190922

SCHEMBL2190922

Cc1nc(Cl)c(C(C)C(=O)O)c(Cl)n1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 3/20 0.34
ALDH1A1 P00352 2/20 0.33
PDK2 Q15119 1/20 0.33
MAPK1 P28482 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
EGLN1 Q9GZT9 4/20 0.33
BBOX1 O75936 2/20 0.33
FTO Q9C0B1 1/20 0.33
CXCL8 P10145 1/20 0.33
AKR1C3 P42330 1/20 0.32
AKR1C2 P52895 1/20 0.32
MAOA P21397 2/20 0.32
ADRA1A P35348 2/20 0.32
HPGD P15428 2/20 0.32
ADRA2C P18825 1/20 0.32
DRD3 P35462 1/20 0.32
KCNH2 Q12809 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12480705 0.85 PTGS2 (0.31) PTGS2ALDH1A1MAPK1SMN1; SMN2EGLN1
SCHEMBL7498747 0.73 KMT2A (0.34) AKR1C3AKR1C2CYP1A2CYP2C9CYP2C19
SCHEMBL16506516 0.73 RECQL (0.34) PDK2
SCHEMBL6575948 0.71 PDE10A (0.46) ALDH1A1EGLN1BBOX1FTOKDM4E
SCHEMBL7505706 0.69 AKR1C3 (0.32) PTGS2ALDH1A1MAPK1SMN1; SMN2AKR1C3
SCHEMBL10004861 0.69 ALDH1A1 (0.57) ALDH1A1PDK2MAPK1SMN1; SMN2HPGD
SCHEMBL10815401 0.68
SCHEMBL856996 0.67 KDM5B (0.30)
SCHEMBL15340789 0.66 ALDH1A1 (0.38) ALDH1A1MAPK1SMN1; SMN2HPGDCYP1A2
SCHEMBL12481055 0.65 PTGS2 (0.32) PTGS2CXCL8AKR1C3AKR1C2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110172255-A1 Condensed N-Heterocyclic Compounds and their Use as CRF Receptor Antagonists SB PHARMCO PUERTO RICO INC 2011-07-14 US disclosed
US-7790715-B2 Organic compounds NOVARTIS AG (CH) 2010-09-07 US disclosed
US-20070010511-A1 Organic compounds NOVARTIS PHARMA AG (CH) 2007-01-11 US disclosed
US-20070004708-A1 Condensed n-heterocyclic compounds and their use as crf receptor antagonists NEUROCRINE BIOSCIENCES, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172255-A1 Condensed N-Heterocyclic Compounds and their Use as CRF Receptor Antagonists CRH, CRHR1, CRHR2 PTGS2 581/4885ALDH1A1 3090/4885PDK2 1708/4885
US-20070010511-A1 Organic compounds REN, ACE, ACE2 PTGS2 279/4885ALDH1A1 142/4885PDK2 321/4885
US-20070004708-A1 Condensed n-heterocyclic compounds and their use as crf receptor antagonists CRHR2, NR3C2, CRHR1 PTGS2 560/4885ALDH1A1 4153/4885PDK2 2842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.